Dissecting Tumor-Immune Interactions in HIV-HPV Co-Infection-Associated Oropharyngeal Cancer using Single Cell Sequencing and Novel Mouse Models
- Institution
- ALBERT EINSTEIN COLLEGE OF MEDICINE, NY
- Principal investigator
- Shanye Yin
- Funding
- $578K
- Duration
- 2024–2029
Moonbase score
Still being scored
Abstract
Project Summary/Abstract Oropharyngeal squamous cell carcinoma (OPSCC) has emerged as a significant global health concern, with increasing incidence attributed to human papillomavirus (HPV) infection. Additionally, individuals living with HIV/AIDS (PLWH) face a higher risk of developing OPSCC. Understanding the synergistic relationships between HIV and oral HPV infection in OPSCC development is critical for advancing prevention, diagnosis, and treatment strategies. CD8+ T cells play a pivotal role in antiviral immunity and tumor surveillance. However, the impact of HIV infection on CD8+ T cells remains largely unexplored. Recently, we have identified an HPV integration hotspot in the PD-L1 gene, contributing to CD8+ T cell exhaustion. In addition, our single-cell analysis revealed a unique subset of exhausted CD8+ T cells associated with HIV-HPV co-infection in the OPSCC microenvironment. We hypothesize that HIV co-infection induces elevated dysfunction/exhaustion of tumor- infiltrating lymphocytes (TILs), particularly CD8+ T cells, in the OPSCC microenvironment. As a multi-PI application, combining our expertise in single-cell analysis and functional analysis of HIV mouse models and CD8+ T cells, we will investigate the impact of HIV infection on the immune cell landscape of HPV-positive OPSCC (Aim 1). Additionally, we will characterize the phenotype and specificity of tumor-infiltrating CD8+ T cell receptors (TCRs) and correlate them with cellular exhaustion status in the context HIV-HPV co-infection (Aim 2). Furthermore, we will establish a novel mouse model that faithfully recapitulates HIV-HPV co-infection in OPSCC to explore dynamic interactions between viral infection, tumor progression, and CD8+ T cells (Aim 3). Additionally, we will investigate the impact of combined antiretroviral therapy (ART) and immune checkpoint blockade on restoring tumor-reactive CD8+ T cell function and preventing HPV-induced neoplastic growth. This research aims to enhance our understanding of HIV-HPV co-infection's influence on immune responses and immune evasion in oropharyngeal cancer. Findings may inform novel therapeutic strategies to enhance immune responses and improve clinical outcomes for OPSCC patients living with HIV and have broader implications for other HPV-associated malignancies.
Research team
- Harris GoldsteinPI
- Shanye YinPI
LOADING MOONBASE SCORE
Questions for ALBERT EINSTEIN COLLEGE OF MEDICINE
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · Albert Einstein College of Medicine62
New Insight of Androgen Signaling in Prostate Cancer Initiation and Progression
Zijie Sun · $197K · 2024–2028
- NIH · Albert Einstein College of Medicine60
"A PHASE I STUDY INVESTIGATING THE SAFETY & EFFICACY OF DANVATIRSEN AS MONOTHERAPY FOLLOWED BY COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MDS & AML."
Aditi Shastri · $650K · 2023–2028
- NIH · Albert Einstein College of Medicine54
MRI study of chemobrain in pediatric oncology patients
Timothy Q. Duong · $377K · 2020–2027